Full‑Process Cost‑Benefit Analysis Of Menghini Needles — For Department Directors And Hospital Administrators
May 17, 2026
Core Keywords
Full‑Process Cost | Benefit Management | Value‑Based Healthcare
Application Scenarios
Formulation and approval of departmental consumable budgets, product evaluation by hospital consumable management committees, administrative decision‑making for controlling medical costs while improving clinical quality.
Selling Points
Beyond simple unit‑price comparison, this paper establishes a total‑cost‑per‑procedure model for liver biopsy. It demonstrates how high‑end Menghini needles deliver greater overall cost savings and clinical value for departments and hospitals by improving diagnostic accuracy, lowering complication rates and reducing repeated procedures - fully aligning with the value‑based healthcare direction under DRG/DIP payment reforms.
Who Is This For?
This article targets directors of hepatology, gastroenterology and interventional departments, hospital procurement leaders for medical consumables, and operational management specialists. You must balance clinical quality and operational costs. When selecting consumables for routine yet critical liver biopsy procedures, the invoice price alone is insufficient; you must calculate the knock‑on effects of each product. A "low‑cost" needle that causes more complications, ambiguous diagnoses and repeated punctures may incur far higher long‑term costs. Together, we calculate the full‑picture economics.
In‑Depth Analysis of Application Scenarios
Assume a department performs 100 liver biopsies monthly and evaluates two Menghini needle options: Needle A with a lower unit price, and Needle B (high‑end precision‑manufactured) priced 30 % higher.
Explicit and implicit costs
From a pure procurement perspective, Needle A appears superior. However, implicit costs must be incorporated:
Cost of repeated punctures: If insufficient sampling or unclear diagnosis with Needle A causes 3 % of cases to require second‑time punctures, 3 additional procedures occur monthly. Each repeat procedure consumes an extra needle set, physician and nursing hours, ultrasound machine time, operating room utilisation, additional disinfection supplies, and exposes patients to further risks and discomfort. These costs far exceed the price difference between the two needles.
Cost of complication management: If manufacturing defects with Needle A slightly raise the incidence of minor complications such as bleeding and haematoma by just 1 %, one extra case occurs monthly. Additional monitoring, medication, prolonged observation time and potential hospitalisation fees rapidly offset savings from lower procurement costs.
Downstream costs from uncertain diagnosis: Poor sample quality leading to non‑definitive pathological reports may require costly follow‑up tests, delayed or adjusted clinical treatment decisions, and even greater losses from misdiagnosis or mistreatment. Though hard to quantify, these impacts are far‑reaching.
Efficiency gains: The higher single‑puncture success rate and smoother operation of Needle B save 5–10 minutes per biopsy. For 100 monthly procedures, this equates to 8–16 hours of saved core medical resources (physicians, ultrasound machines, operating rooms). Freed‑up capacity enables care for more patients and generates incremental value.
Brand and risk value: Reliable high‑end products reduce medical safety risks and improve patient satisfaction, helping departments and hospitals build a high‑quality, trustworthy brand image with long‑term value in today's patient‑centred healthcare landscape.
Comparative Advantages: Decision‑Making Upgrade from Lowest Unit Price to Optimal Total Cost
Administrative decisions should be guided by comprehensive cost‑benefit analysis.
| Comparison Dimension | Conventional Menghini Needle (Needle A) | High‑End Precision‑Manufactured Menghini Needle (Needle B) | Strategic Administrative Value |
|---|---|---|---|
| Unit Procurement Cost | ¥100 | ¥130 (30 % higher) | Higher upfront expenditure |
| Single‑Puncture Success Rate | 94 % | 99 % | Reduces repeated punctures and full costs of secondary procedures |
| Diagnostic Adequacy of Samples | 90 % | 98 % | Cuts downstream medical costs from repeat tests or consultations caused by unclear diagnosis |
| Puncture‑Related Complication Rate | 1.5 % | 0.5 % | Directly lowers complication‑management expenses and medical risks |
| Average Procedure Duration | 25 minutes | 20 minutes | Improves turnover efficiency of medical resources and potentially expands service capacity |
| Estimated Monthly Total Cost (100 cases) | Procurement + repeat‑procedure + complication + time costs = Higher | Procurement + minimal repeat‑procedure/complication/time costs = Potentially lower or equivalent | High‑end needles may deliver superior total‑cost performance alongside overall improvements in quality, safety and efficiency |
Conclusion
For department and hospital administrators, adopting a full‑process cost‑benefit analysis model for liver biopsy needle selection marks progress toward refined and intelligent healthcare management. While high‑end precision‑manufactured Menghini needles increase direct costs in the short term, they may represent the most cost‑effective cost‑reduction and efficiency‑boosting solution long‑term. By ensuring single‑attempt success, definitive diagnosis and maximum safety, they systematically eliminate substantial waste and potential risks. Against the backdrop of medical insurance payment reforms emphasising retained surpluses, products that reduce complications, improve treatment efficiency and guarantee clinical quality enable a win‑win balance between enhanced medical quality and cost control.
